{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-023902","form_type":"8-K","ticker":"ORGO","cik":"0001661181","company_name":"Organogenesis Holdings Inc.","filed_at":"2022-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.612118+00:00","generated_at":"2026-06-22T01:28:28.856668+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Organogenesis Q3 net income plummets to $0.2M on $116.9M revenue; cuts FY2022 guidance","bullets":["Net revenue $116.9M (+3% YoY), but net income $0.2M vs $12.6M in Q3 2021.","Adjusted EBITDA $11.6M, down 46% YoY; adjusted net income $5.1M, down 68%.","FY2022 revenue guidance lowered to $448-465M, citing challenging physician office environment and reimbursement uncertainty.","SG&A expenses surged 27% to $79.3M, pressuring margins.","Cash $108M, debt $72.6M; no share repurchase or dividend changes."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-023902","json":"https://secwatch.observer/filing/0000950170-22-023902.json","markdown":"https://secwatch.observer/filing/0000950170-22-023902.md","text":"https://secwatch.observer/filing/0000950170-22-023902.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661181/000095017022023902/0000950170-22-023902-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661181/000095017022023902/orgo-20221109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T01:28:28.856668+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c4babc86d6e20425a8c6e073aed2c80cee025460","claim":"Organogenesis Holdings Inc. reported third quarter ended September 30, 2022 results: revenue $116.9 million, net income $0.2 million, EPS $0.00 per share. Guidance lowered.","evidence_excerpt":"& Sports Medicine markets, today reported financial results for the third quarter ended September 30, 2022. Third Quarter 2022 Financial Results Summary: • Net revenue of $116.9 million for the third quarter of 2022, an increase of 3% compared to net revenue of $113.8 million for the third quarter of 2021. Net revenue for the third quarter of 2022 consists of: o","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1661181/000095017022023902/0000950170-22-023902-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Revenue","value":"$116.9 million"},{"label":"Net income","value":"$0.2 million"},{"label":"EPS","value":"$0.00 per share"},{"label":"Guidance","value":"lowered"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}